How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes

    Closed for comments This consultation ended on at   Request commenting lead permission

    References

    1. Mingrone G, van Baar AC, Devière J et al. (2022) Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut, 71(2), 254-264

    2. van Baar AC, Devière J, Hopkins D et al. (2022) Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study). Diabetes research and clinical practice, 184, 109194

    3. van Baar AC, Meiring S, Smeele P et al. (2021) Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study. Gastrointestinal Endoscopy, 94(1), 111-120

    4. Meiring S, Busch CBE, van Baar ACG et al. (2022) Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events. Cardiovascular Diabetology, 21(1), 1-8

    5. Rajagopalan H, Cherrington AD, Thompson CC et al. (2016) Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care, 39(12), 2254-2261